End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
121,300 KRW | -3.12% | -2.49% | -3.35% |
Business Summary
Number of employees: 2,098
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Manufacturing and Sales of Pharmaceuticals, Etc.
88.6
%
| 1,484,485 | 86.7 % | 1,440,879 | 88.6 % | -2.94% |
Diagnosis and Analysis of Samples, Etc.
13.1
%
| 262,178 | 15.3 % | 213,763 | 13.1 % | -18.47% |
Consolidation
-2.9
%
| -57,445 | -3.4 % | -46,494 | -2.9 % | -19.06% |
Other
1.1
%
| 22,095 | 1.3 % | 18,496 | 1.1 % | -16.29% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
86.1
%
| 1,462,048 | 85.4 % | 1,400,272 | 86.1 % | -4.23% |
Overseas
16.8
%
| 306,710 | 17.9 % | 272,866 | 16.8 % | -11.03% |
Consolidation
-2.9
%
| -57,445 | -3.4 % | -46,494 | -2.9 % | -19.06% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eun-Cheol Huh
CEO | Chief Executive Officer | 52 | 05-12-31 |
Ok-Gyu Go
CMP | Compliance Officer | - | 13-12-31 |
In-Jae Lee
BRD | Director/Board Member | 61 | - |
Byeong-Hwa Kim
BRD | Director/Board Member | 65 | - |
Young-Tae Lee
AUD | Comptroller/Controller/Auditor | 67 | - |
Pyeong-Joo Jang
PRN | Corporate Officer/Principal | 62 | - |
Il-Sup Huh
PRN | Corporate Officer/Principal | 69 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Il-Sup Huh
PRN | Corporate Officer/Principal | 69 | - |
Eun-Cheol Huh
CEO | Chief Executive Officer | 52 | 05-12-31 |
Byeong-Hwa Kim
BRD | Director/Board Member | 65 | - |
In-Jae Lee
BRD | Director/Board Member | 61 | - |
Choon-Woo Lee
BRD | Director/Board Member | 58 | - |
Yoon-Jae Choi
BRD | Director/Board Member | 69 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,686,538 | 5,399,343 ( 46.20 %) | 273,360 ( 2.339 %) | 46.20 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GC CELL CORPORATION 33.28% | 5,257,712 | 33.28% | 156,752,164 $ |
3,920,250 | 22.08% | 32,443,048 $ | |
8,765,704 | 41.47% | 28,141,591 $ | |
GC BIOPHARMA CORP. 2.34% | 273,360 | 2.34% | 24,203,322 $ |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.35% | 1.03B | |
+33.46% | 701B | |
+26.24% | 569B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+2.95% | 212B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock GC Biopharma Corp. - Korea S.E.
- Company GC Biopharma Corp.